MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyae182

Медицинская библиотека · The oncologist · 2025

Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma.

Yousef Mahmoud, Hurd Mark W, Yousef Abdelrahman, Ludmir Ethan B, Pillai Ashwathy B, Peterson Jennifer, Koay Eugene J, Albarouki Sali, Tzeng Ching-Wei, Snyder Rebecca, Katz Matthew H G, Wang Huamin, Overman Michael J, Maitra Anirban, Pant Shubham, Smaglo Brandon G, Wolff Robert A, Yao James, Shen John P, Zhao Dan

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

BACKGROUND

The prognosis for patients with pancreatic ductal adenocarcinoma (PDAC) is poor. Secondary brain metastasis (Br-M) occurs in less than 1% of patients. Clinical characteristics and molecular alterations have not been characterized in this rare patients' subset.

MATERIALS AND

METHODS

The Foundry software platform was used to retrospectively query electronic health records for patients with Br-M secondary to PDAC from 2005 to 2023; clinical, molecular, and overall survival (OS) data were analyzed.

RESULTS

Br-M was diagnosed in 44 patients with PDAC. Median follow-up was 78 months; median OS from initial PDAC diagnosis was 47 months. Median duration from PDAC diagnosis to Br-M detection was 24 months; median OS from Br-M diagnosis was 3 months. At Br-M diagnosis, 82% (n = 36) of patients had elevated CA19-9. Lung was the most common preexisting metastatic location (71%) with Br-M, followed by liver (66%). Br-M were most frequently observed in the frontal lobe (34%, n = 15), cerebellar region (23%, n = 10), and leptomeninges (18%, n = 8). KRAS mutations were detected in 94.1% (n = 16) of patients who had molecular data available (n = 17) with KRASG12V being the most frequent subtype 47% (n = 8); KRASG12D in 29% (n = 5); KRASG12R in 18% (n = 3). Patients who underwent Br-M surgical resection (n = 5) had median OS of 8.6 months, while median OS following stereotactic radiosurgery only (n = 11) or whole-brain radiation only (n = 20) was 3.3 and 2.8 months, respectively.

CONCLUSION

Br-M is a late PDAC complication, resulting in an extremely poor prognosis especially in leptomeningeal disease. KRAS was mutated in 94.1% of the patients and the KRASG12V subtype was prevalent.

Для цитирования: Yousef Mahmoud, Hurd Mark W, Yousef Abdelrahman, Ludmir Ethan B, Pillai Ashwathy B, Peterson Jennifer, Koay Eugene J, Albarouki Sali, Tzeng Ching-Wei, Snyder Rebecca, Katz Matthew H G, Wang Huamin, Overman Michael J, Maitra Anirban, Pant Shubham, Smaglo Brandon G, Wolff Robert A, Yao James, Shen John P, Zhao Dan. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma.. The oncologist. 2025. DOI: 10.1093/oncolo/oyae182.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.